each building of the standardization system further
enhances protection for innovation.
following the iso27001 information security
management system certification, tot biopharm (stock code: 1875.hk) has
recently received good news that the company has successfully passed the
gb/t29490-2013 enterprise intellectual property management system
certification, which means that tot biopharm has established a set of
well-conceived and standardized intellectual property management system in line
with national standards, and it is also another validation of tot biopharm’s
commitment of respecting intellectual property rights, safeguarding the legal
rights of clients, and protecting innovation for customers and partners.
the enterprise intellectual property management
standard (gb/t29490-2013) is a national standard formulated
by the china national intellectual property administration. “implementation of
the standard”, that is, implementation of the the enterprise intellectual
property management standard, which is the most effective way for
enterprises to integrate ip. this certification on “implementation of the
standard” strengthens the comprehensive management by tot biopharm over ip and
further enhance the company’s capability in ip management.
ip protection is a key concern for every
pharmaceutical enterprise, and it is especially important for cdmo companies to
manage ip effectively to protect innovative results of their clients. this certification
will put standardized ip management into practices through all aspects
including the r&d and manufacture, thus further enhancing the security and
standardization of tot biopharm’s cdmo services, and ensuring customers’ peace
of mind by protecting their ip in an effective way.
tot biopharm is committed to being a better
biopharmaceutical partner leading the industry and trusted by customers. with
extensive practical experience, as well as sophisticated technology platform
and quality system, we provide customized one-stop cdmo solutions for
biopharmaceuticals from r&d to commercial manufacture based on the needs of
different partners. as well, tot biopharm will continue to strengthen and
improve the management of intellectual property rights and maintain the
effective and continuous operation of the system in order to live up to the
trust of our clients and protect the development of cdmo business.